JP2022541916A - ソフトチュアブル獣医学用投与形態 - Google Patents

ソフトチュアブル獣医学用投与形態 Download PDF

Info

Publication number
JP2022541916A
JP2022541916A JP2022503974A JP2022503974A JP2022541916A JP 2022541916 A JP2022541916 A JP 2022541916A JP 2022503974 A JP2022503974 A JP 2022503974A JP 2022503974 A JP2022503974 A JP 2022503974A JP 2022541916 A JP2022541916 A JP 2022541916A
Authority
JP
Japan
Prior art keywords
soft
dosage form
core material
binder
physiologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022503974A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541916A5 (enExample
Inventor
ノースラップ，ラウラ・アン
フリーホーフ，キース
ウォルドロン，ニキ
サスコ，ティモシー
Original Assignee
インターベット インターナショナル ベー． フェー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターベット インターナショナル ベー． フェー． filed Critical インターベット インターナショナル ベー． フェー．
Publication of JP2022541916A publication Critical patent/JP2022541916A/ja
Publication of JP2022541916A5 publication Critical patent/JP2022541916A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
JP2022503974A 2019-07-22 2020-07-21 ソフトチュアブル獣医学用投与形態 Pending JP2022541916A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962877070P 2019-07-22 2019-07-22
US62/877,070 2019-07-22
PCT/EP2020/070527 WO2021013825A1 (en) 2019-07-22 2020-07-21 Soft chewable veterinary dosage form

Publications (2)

Publication Number Publication Date
JP2022541916A true JP2022541916A (ja) 2022-09-28
JP2022541916A5 JP2022541916A5 (enExample) 2023-07-24

Family

ID=71842655

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022503974A Pending JP2022541916A (ja) 2019-07-22 2020-07-21 ソフトチュアブル獣医学用投与形態

Country Status (9)

Country Link
US (1) US20220323421A1 (enExample)
EP (1) EP4003292A1 (enExample)
JP (1) JP2022541916A (enExample)
CN (1) CN114144172A (enExample)
AU (1) AU2020316642B2 (enExample)
BR (1) BR112022000982A2 (enExample)
CA (1) CA3146043A1 (enExample)
MX (1) MX2022000843A (enExample)
WO (1) WO2021013825A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022066A1 (en) 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
AU2018385766B2 (en) 2017-12-15 2022-12-01 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
BR112021019931A2 (pt) * 2019-04-04 2021-12-07 Tarsus Pharmaceuticals Inc Parasiticidas isoxazolina sistêmicos para tratamento ou profilaxia de doença transmitida por vetor e viral
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
CA3164924A1 (en) 2019-12-18 2021-06-24 Elanco Tiergesundheit Ag Isoxazoline derivatives as pesticides
AU2021311722A1 (en) 2020-07-24 2023-02-02 Elanco Us Inc. Process for making an isoxazoline compound and intermediate thereof
EP4208157A1 (en) 2020-09-04 2023-07-12 Elanco Us Inc. Palatable formulations
WO2023198476A1 (en) * 2022-04-15 2023-10-19 Krka, D.D., Novo Mesto Soft chewable veterinary dosage form
CN117122571A (zh) * 2022-05-20 2023-11-28 天津瑞普生物技术股份有限公司 一种抗寄生虫感染的口服药物制剂及其制备方法和应用
FR3138315A1 (fr) 2022-07-27 2024-02-02 Virbac Produit à usage vétérinaire et procédé pour sa fabrication

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007500004A (ja) * 2003-07-30 2007-01-11 ノバルティス アクチエンゲゼルシャフト 口当たりが良く、延性がある、咀嚼可能な家畜用組成物
JP2007514446A (ja) * 2003-12-19 2007-06-07 メリアル リミテッド 安定化されたイベルメクチン飼料プレミックス製剤
JP2015512435A (ja) * 2012-04-04 2015-04-27 インターベット インターナショナル ベー． フェー． イソオキサゾリン化合物のための固形経口医薬組成物
JP2016507472A (ja) * 2012-11-20 2016-03-10 インターベット インターナショナル ベー． フェー． 半可塑性医薬投与単位の製造

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4914624A (enExample) 1972-06-08 1974-02-08
US3950360A (en) 1972-06-08 1976-04-13 Sankyo Company Limited Antibiotic substances
SE434277B (sv) 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4134973A (en) 1977-04-11 1979-01-16 Merck & Co., Inc. Carbohydrate derivatives of milbemycin and processes therefor
US4199569A (en) 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
US4144352A (en) 1977-12-19 1979-03-13 Merck & Co., Inc. Milbemycin compounds as anthelmintic agents
US4203976A (en) 1978-08-02 1980-05-20 Merck & Co., Inc. Sugar derivatives of C-076 compounds
JPS57139012A (en) 1981-02-23 1982-08-27 Sankyo Co Ltd Anthelmintic composition
US4427663A (en) 1982-03-16 1984-01-24 Merck & Co., Inc. 4"-Keto-and 4"-amino-4"-deoxy avermectin compounds and substituted amino derivatives thereof
EP0237482A1 (de) 1986-03-06 1987-09-16 Ciba-Geigy Ag C(29)-Carbonyloxi-milbemycin-Derivate zur Bekämpfung von tier- und pflanzenparasitären Schädlingen
EP0342710B1 (en) 1986-03-25 1993-05-19 Sankyo Company Limited Macrolide compounds, their preparation and their use
ATE75745T1 (de) 1986-07-02 1992-05-15 Ciba Geigy Ag Pestizide.
US4855317A (en) 1987-03-06 1989-08-08 Ciba-Geigy Corporation Insecticides and parasiticides
US4871719A (en) 1987-03-24 1989-10-03 Ciba-Geigy Corporation Composition for controlling parasites in productive livestock
US4874749A (en) 1987-07-31 1989-10-17 Merck & Co., Inc. 4"-Deoxy-4-N-methylamino avermectin Bla/Blb
DE3888936T2 (de) 1987-11-03 1994-07-21 Beecham Group Plc Zwischenprodukte für die Herstellung makrolider Antibiotika mit anthelmintischer Wirkung.
NZ232422A (en) 1989-02-16 1992-11-25 Merck & Co Inc 13-ketal milbemycin derivatives and parasiticides
NZ247278A (en) 1991-02-12 1995-03-28 Ancare Distributors Veterinary anthelmintic drench comprising a suspension of praziquantel in a liquid carrier
GB9300883D0 (en) 1993-01-18 1993-03-10 Pfizer Ltd Antiparasitic agents
AUPM969994A0 (en) 1994-11-28 1994-12-22 Virbac S.A. Equine anthelmintic formulations
AU2005219788B2 (en) 2004-03-05 2010-06-03 Nissan Chemical Corporation Isoxazoline-substituted benzamide compound and noxious organism control agent
US20060068020A1 (en) * 2004-09-24 2006-03-30 Cottrell Ian W Encapsulated pharmaceutical agents
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
ES2549731T3 (es) 2007-06-27 2015-11-02 E. I. Du Pont De Nemours And Company Método para el control de plagas en animales
TWI556741B (zh) 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用
TWI411395B (zh) 2007-12-24 2013-10-11 Syngenta Participations Ag 殺蟲化合物
ES2442342T3 (es) 2008-12-18 2014-02-11 Novartis Ag Derivados de las isoxazolinas y su uso como pesticida
CA2747354C (en) 2008-12-19 2016-12-06 Novartis Ag Isoxazoline derivatives and their use as pesticide
LT2811998T (lt) 2012-02-06 2019-02-25 Merial, Inc. Paraziticidinės peroralinės veterinarinės kompozicijos, apimančios sistemiškai veikiančius aktyviuosius agentus, būdai ir jų panaudojimas
WO2015086551A1 (en) 2013-12-10 2015-06-18 Intervet International B.V. Antiparasitic use of isoxazoline compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007500004A (ja) * 2003-07-30 2007-01-11 ノバルティス アクチエンゲゼルシャフト 口当たりが良く、延性がある、咀嚼可能な家畜用組成物
JP2007514446A (ja) * 2003-12-19 2007-06-07 メリアル リミテッド 安定化されたイベルメクチン飼料プレミックス製剤
JP2015512435A (ja) * 2012-04-04 2015-04-27 インターベット インターナショナル ベー． フェー． イソオキサゾリン化合物のための固形経口医薬組成物
JP2015514103A (ja) * 2012-04-04 2015-05-18 インターベット インターナショナル ベー． フェー． ソフトなチュアブル医薬製品
JP2016507472A (ja) * 2012-11-20 2016-03-10 インターベット インターナショナル ベー． フェー． 半可塑性医薬投与単位の製造

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VETERINARY PARASITOLOGY, vol. 225, JPN6024025320, 2016, pages 117 - 122, ISSN: 0005567602 *

Also Published As

Publication number Publication date
BR112022000982A2 (pt) 2022-03-08
AU2020316642B2 (en) 2025-10-23
CA3146043A1 (en) 2021-01-28
EP4003292A1 (en) 2022-06-01
CN114144172A (zh) 2022-03-04
MX2022000843A (es) 2022-02-10
US20220323421A1 (en) 2022-10-13
WO2021013825A1 (en) 2021-01-28
AU2020316642A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
JP2022541916A (ja) ソフトチュアブル獣医学用投与形態
KR102077874B1 (ko) 연질 저작성 제약 제품
ES2743673T3 (es) Composiciones parasiticidas orales veterinarias que comprenden agentes activos de acción sistémica, procedimientos y usos de las mismas
CA2965524C (en) Palatable chewable veterinary composition
ES2731881T3 (es) Composiciones que comprenden compuestos activos lipófilos y método para su preparación
KR102227869B1 (ko) 반소성 제약 투여 단위의 제조
EP0729748B1 (en) Process for producing stable medicinal composition
KR20240025534A (ko) 맛우수한 수의학적 조성물
JP5319691B2 (ja) プラジカンテル、マクロライドラクトン、シクロデキストリンおよび粘稠化剤を含む駆虫ペースト
JP7447315B2 (ja) 注射可能な医薬組成物及びその使用
ES2284980T3 (es) Microesferulas que contienen un derivado pleuromutilina.
RU2824778C2 (ru) Мягкая жевательная ветеринарная лекарственная форма
MXPA06002530A (es) Forma de dosificacion oral, en forma de multiples particulas, formulada mediante fusion.
KR20210150501A (ko) Hcv를 치료하기 위한 고체 약제학적 조성물
AU2007100254A4 (en) Improved parasiticide paste
DK2833866T3 (en) SOFT PHARMACEUTICAL CHAVE PRODUCTS
HK1092715B (en) Melt-formulated, multi-particulate oral dosage form

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230713

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250408